Search Results

There are 34454 results for: content related to: Expression of drug pathway proteins is independent of tumour type

  1. You have free access to this content
    Heat shock protein 27 is associated with irinotecan resistance in human colorectal cancer cells

    FEBS Letters

    Volume 581, Issue 8, April 17, 2007, Pages: 1649–1656, Dae Hwa Choi, Jin Sook Ha, Won Hyuck Lee, Jeong Kee Song, Gyu Yeol Kim, Jae Hoo Park, Hee Jeong Cha, Byung Ju Lee and Jeong Woo Park

    Version of Record online : 22 MAR 2007, DOI: 10.1016/j.febslet.2007.02.075

  2. You have free access to this content
    Targeted inhibition of IL-18 attenuates irinotecan-induced intestinal mucositis in mice

    British Journal of Pharmacology

    Volume 171, Issue 9, May 2014, Pages: 2335–2350, R C P Lima-Júnior, H C Freitas, D V T Wong, C W S Wanderley, L G Nunes, L L Leite, S P Miranda, M H L P Souza, G A C Brito, P J C Magalhães, M M Teixeira, F Q Cunha and R A Ribeiro

    Version of Record online : 11 APR 2014, DOI: 10.1111/bph.12584

  3. Second-line systemic therapy for metastatic colorectal cancer

    Intervention Review

    The Cochrane Library

    Simone Mocellin, Zora Baretta, Marta Roqué i Figuls, Ivan Solà, Marta Martin-Richard, Sara Hallum and Xavier Bonfill Cosp

    Published Online : 27 JAN 2017, DOI: 10.1002/14651858.CD006875.pub3

  4. UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice

    Fundamental & Clinical Pharmacology

    Volume 29, Issue 3, June 2015, Pages: 219–237, Marie-Christine Etienne-Grimaldi, Jean-Christophe Boyer, Fabienne Thomas, Sylvie Quaranta, Nicolas Picard, Marie-Anne Loriot, Céline Narjoz, Delphine Poncet, Marie-Claude Gagnieu, Cécile Ged, Franck Broly, Valérie Le Morvan, Régis Bouquié, Marie-Pierre Gaub, Laurent Philibert, François Ghiringhelli, Chantal Le Guellec and Collective work by the Groupe de Pharmacologie Clinique Oncologique (GPCO-Unicancer) and the French Réseau National de Pharmacogénétique Hospitalière (RNPGx)

    Version of Record online : 4 MAY 2015, DOI: 10.1111/fcp.12117

  5. Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure

    The Journal of Clinical Pharmacology

    Volume 55, Issue 11, November 2015, Pages: 1303–1312, Alexander K. Berg, Jan C. Buckner, Evanthia Galanis, Kurt A. Jaeckle, Matthew M. Ames and Joel M. Reid

    Version of Record online : 26 JUN 2015, DOI: 10.1002/jcph.543

  6. Cetuximab increases concentrations of irinotecan and of its active metabolite SN-38 in plasma and tumour of human colorectal carcinoma-bearing mice

    Fundamental & Clinical Pharmacology

    Volume 28, Issue 6, December 2014, Pages: 652–660, Céline Chu, Chadi Abbara, Mahamadou Tandia, Mélanie Polrot, Patrick Gonin, Robert Farinotti and Laurence Bonhomme-Faivre

    Version of Record online : 16 APR 2014, DOI: 10.1111/fcp.12071

  7. You have full text access to this OnlineOpen article
    Comet assay measures of DNA damage as biomarkers of irinotecan response in colorectal cancer in vitro and in vivo

    Cancer Medicine

    Volume 4, Issue 9, September 2015, Pages: 1309–1321, Joanna P. Wood, Andrew J. O. Smith, Karen J. Bowman, Anne L. Thomas and George D. D. Jones

    Version of Record online : 23 JUN 2015, DOI: 10.1002/cam4.477

  8. You have free access to this content
    Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients

    Cancer

    Volume 118, Issue 12, 15 June 2012, Pages: 3173–3181, C. Daniel Mullins, Fei-Yuan Hsiao, Eberechukwu Onukwugha, Naimish B. Pandya and Nader Hanna

    Version of Record online : 21 OCT 2011, DOI: 10.1002/cncr.26613

  9. You have free access to this content
    Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors

    Cancer

    Volume 115, Issue 1, 1 January 2009, Pages: 207–216, Adam S. Levy, Paul A. Meyers, Leonard H. Wexler, Regina Jakacki, Anne Angiolillo, Sarah N. Ringuette, Marvin B. Cohen, Richard Gorlick and Other site principal investigators: Wayne Furman, MD (St. Jude Children's Research Hospital, Memphis, Tennessee); Rochelle Bagatell, MD (University of Arizona Health Sciences Center, Tucson, Arizona); Lori Luchtman-Jones, MD (Washington University School of Medicine, St. Louis, Missouri); Luis Eduardo Garcia, MD (Hospital CIMA, San Jose, Costa Rica); and Eric Sandler, MD (Nemours Children's Clinic, Jacksonville, Florida).

    Version of Record online : 17 DEC 2008, DOI: 10.1002/cncr.23992

  10. Caspase-mediated pro-apoptotic interaction of panaxadiol and irinotecan in human colorectal cancer cells

    Journal of Pharmacy and Pharmacology

    Volume 64, Issue 5, May 2012, Pages: 727–734, Guang-Jian Du, Chong-Zhi Wang, Zhi-Yu Zhang, Xiao-Dong Wen, Jacqueline Somogyi, Tyler Calway, Tong-Chuan He, Wei Du and Chun-Su Yuan

    Version of Record online : 21 FEB 2012, DOI: 10.1111/j.2042-7158.2012.01463.x

  11. DNA Topoisomerase Targeting Drugs

    Standard Article

    Holland-Frei Cancer Medicine

    Anish Thomas, Susan Bates, William D. Figg and Yves Pommier

    Published Online : 26 FEB 2017, DOI: 10.1002/9781119000822.hfcm060

  12. Renal Function as a Predictor of Irinotecan-induced Neutropenia

    Clinical Pharmacology & Therapeutics

    Volume 84, Issue 2, August 2008, Pages: 254–262, FA de Jong, JM van der Bol, RHJ Mathijssen, T van Gelder, EAC Wiemer, A Sparreboom and J Verweij

    Version of Record online : 20 FEB 2008, DOI: 10.1038/sj.clpt.6100513

  13. Camptothecin and Its Analogs

    Annals of the New York Academy of Sciences

    Volume 803, Issue 1, December 1996, Pages: 213–223, FRANCO M. MUGGIA, ISAIAH DIMERY and SUSAN G. ARBUCK

    Version of Record online : 17 DEC 2006, DOI: 10.1111/j.1749-6632.1996.tb26391.x

  14. Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors

    Pediatric Blood & Cancer

    Volume 54, Issue 7, 1 July 2010, Pages: 909–915, René Y. McNall-Knapp, Cydni N. Williams, Elaine N. Reeves, Richard L. Heideman and William H. Meyer

    Version of Record online : 14 APR 2010, DOI: 10.1002/pbc.22460

  15. Chemotherapy for advanced gastric cancer

    Intervention Review

    The Cochrane Library

    Anna Dorothea Wagner, Nicholas LX Syn, Markus Moehler, Wilfried Grothe, Wei Peng Yong, Bee-Choo Tai, Jingshan Ho and Susanne Unverzagt

    Published Online : 29 AUG 2017, DOI: 10.1002/14651858.CD004064.pub4

  16. You have free access to this content
    Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer

    Cancer

    Volume 110, Issue 1, 1 July 2007, Pages: 138–147, Ji-Youn Han, Hyeong-Seok Lim, Yeon-Kyeong Yoo, Eun Soon Shin, Yong Hoon Park, Sung Young Lee, Jong-Eun Lee, Dea Ho Lee, Heung Tae Kim and Jin Soo Lee

    Version of Record online : 29 MAY 2007, DOI: 10.1002/cncr.22760

  17. You have free access to this content
    Thromboxane A2, released by the anti- tumour drug irinotecan, is a novel stimulator of Cl secretion in isolated rat colon

    The Journal of Physiology

    Volume 505, Issue 1, November 1997, Pages: 133–144, Hideki Sakai, Takahiro Sato, Noriko Hamada, Miyuki Yasue, Akira Ikari, Bunpei Kakinoki and Noriaki Takeguchi

    Version of Record online : 30 SEP 2004, DOI: 10.1111/j.1469-7793.1997.133bc.x

  18. You have free access to this content
    Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies

    Cancer

    Volume 118, Issue 24, 15 December 2012, Pages: 6144–6151, Razelle Kurzrock, Sanjay Goel, Jennifer Wheler, David Hong, Siqing Fu, Keyvan Rezai, Sonia K. Morgan-Linnell, Saik Urien, Sridhar Mani, Imran Chaudhary, Mohammed H. Ghalib, Aby Buchbinder, François Lokiec and Mary Mulcahy

    Version of Record online : 6 JUN 2012, DOI: 10.1002/cncr.27647

  19. Pharmacokinetic interactions in mice between irinotecan and MBL-II-141, an ABCG2 inhibitor

    Biopharmaceutics & Drug Disposition

    Volume 38, Issue 5, July 2017, Pages: 351–362, Emilie Hénin, Mylène Honorat, Jérôme Guitton, Attilio Di Pietro, Léa Payen and Michel Tod

    Version of Record online : 23 MAR 2017, DOI: 10.1002/bdd.2069

  20. Hepatic extraction, metabolism, and biliary excretion of irinotecan in the isolated perfused rat liver

    Journal of Pharmaceutical Sciences

    Volume 90, Issue 6, June 2001, Pages: 722–731, Christian Farabos, Marie-Christine Haaz, Pierre Gires and Jacques Robert

    Version of Record online : 8 MAY 2001, DOI: 10.1002/jps.1028